Physician profile
Joseph Baar
NPI 1346269230
$7,163.72
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,186 · 2021: $2,870 · 2022: $107.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,166.66 | 2019 | |
| Merck Sharp & Dohme LLC | $2,750.00 | 2021 | |
| Genzyme Corporation | $41.09 | 2019-2022 | |
| Amgen INC. | $40.96 | 2022 | |
| Epizyme, INC. | $27.80 | 2021 | |
| Aveo Pharmaceuticals, INC. | $19.80 | 2021 | |
| Incyte Corporation | $17.30 | 2021 | |
| Blueprint Medicines Corporation | $16.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.76 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.64 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.49 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Beigene USA, INC. | $11.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Baar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.